Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - Implications for pharmacokinetics of selected substrates

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 8, 2004, Pages 967-975

  El Ela, Amal Abou ^a   Härtter, Sebastian ^a   Schmitt, Ulrich ^a   Hiemke, Christoph ^a   Spahn Langguth, Hildegard ^a   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMISULPRIDE; CLOZAPINE; CYCLOSPORIN A; DOMPERIDONE; DRUG CARRIER; FLUPENTIXOL; FLUPHENAZINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; NEUROLEPTIC AGENT; PERAZINE; PERPHENAZINE; QUETIAPINE; RADIOLIGAND; TALINOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL STRAIN CACO 2; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIPOPHILICITY; MALE; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; RADIOASSAY; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CACO-2 CELLS; CYCLOSPORINE; DRUG INTERACTIONS; FLUPHENAZINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; P-GLYCOPROTEINS; RATS; SUBSTRATE SPECIFICITY; SULPIRIDE; TISSUE DISTRIBUTION;

EID: 4344701123     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357043969     Document Type: Article

References (30)

1. Abou El Ela, A. (2003) Implications of physicochemical parameters for carrier-mediated and passive membrane transport for psychoactive drugs. Ph.D. thesis, Johannes Gutenberg-University, Mainz
2. Albert, A., Seargent, E. P. (1984) The determination of ionization constant. A Laboratory manual, 3rd edn. Chapman and Hall, New York
3. Avdeef, A., Box, K. J., Comer, J. E., Gilges, M., Hadley, M., Hibbert, C., Patterson, W., Tam, K. Y. (1999) pH-metric log P11. pka determination of water-insoluble drugs in organic solvent-water mixtures. J. Pharm. Biomed. Anal. 20: 631-641
4. Bertilsson, L., Dahl, M.-L. (1996) Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223
5. Boulton, D. W., DeVane, C. L., Liston, H. L., Markowitz, J. S. (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71: 163-169
6. Cooper, J. K., Hawes, E. M., Hubbart, J. W., McKay, G., Midha, K. K. (1989) An ultrasensitive method for the measurement of fluphenazine in HPLC with coulometric detection. Ther. Drug Monit. 11: 354-360
7. Döppenschmitt, S., Spahn-Langguth, H., Regårdh, C. G., Langguth, P. (1998) Radioligand-binding assay employing P-glycoprotein overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm. Res. 15: 1001-1006
8. Ford, J. M., Prozialeck, W. C., Hait, W. N. (1989) Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35: 105-115
9. Hanafy, A. (2001) Transport inhibition and induction as sources for absorption- and disposition-related drug-drug interactions: talinolol as model substrate for the ABC-transporter P-glycoprotein. Ph.D. thesis, Department of Pharmaceutical Chemistry, Martin-Luther-University, Halle-Wittenberg, FRG
10. Härtter, S., Hiemke, C. (1992) Column switching and high-performance liquid chromatography in the analysis of amitriptyline and hydroxylated metabolites in human plasma or serum. J. Chromatogr. 578: 273-282
11. Härtter, S., Hüwel, S., Lohmann, T., Abou El Ela, A., Langguth, P., Hiemke, C., Galla, H.-J. (2003) How does the benzamide antipsychotic amisulpride get into the brain? An in vitro approach comparing amisulpride with clozapine. Psychopharmacology 28: 1916-1922
12. Kataoka, Y., Ishikawa, M., Miura, M., Takeshita, M., Fujita, R., Furusawa, S., Takayanagi, M., Takayanagi, Y., Sasaki, K. (2001) Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol. Biol. Pharm. Bull. 24: 612-617
13. Kim, R. B (2003) Drug transporters in HIV therapy. Top. HIV Med. 11: 136-139
14. Koggel, A. (2002) Influence of secretary transporters on the intestinal permeability of cationic drugs. Ph.D. thesis, Johannes Gutenberg-University, Mainz
15. Leisen, C., Langguth, P., Herber, B., Dressler, C., Koggel, A., Spahn-Langguth, H. (2003) Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: relevance for their permeation across the blood-brain barrier? Pharm. Res. 20: 772-778
16. Nemeroff, C. B., de Vane, C. L., Pollock, B. G. (1996) Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153: 311-320
17. Prior, T. I., Baker, G. B. (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 28: 99-112
18. Sachse, J., Härrter, S., Weigmann, H., Hiemke, C. (2003) Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 784: 405-410
19. Schinkel, A. H., Wagenaar, E., Mol, C. A., van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97: 2517-2524
20. Seelig, A. (1998) A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251: 252-261
21. Seelig, A., Landwojtowicz, E. (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 12: 31-40
22. Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Teerhag, B., Ader, P., Hanafy, A., Langguth, P. (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36: 16-24
23. Stouch, T. R., Gudmundsson, O. (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Del. Rev. 54: 315-328
24. Suzuki, H., Terasaki, T., Sugiyama, Y. (1997) Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Del. Rev. 25: 257-285
25. Taylor, D. (1995) Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Br. J. Psychiatry 167: 575-580
26. Tsuji, A., Tamai, I. (1996) Carrier-mediated intestinal transport of drugs. Pharm. Res. 13: 963-977
27. Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972
28. Uhr, M., Grauer, M. T., Holsboer, F. (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 54: 840-846
29. Wang, J.-S., Taylor, R., Ruan, Y., Donovan, J. L., Markowitz, J. S., de Vane, C. L. (2004) Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVBI (Wild-type) animals. Neuropsychopharmacology 29: 551-557
30. Zong, J., Pollack, G. M. (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J. Pharmacol. Exp. Ther. 306: 556-562